Earnings call transcript: Campari Group confirms growth streak in Q3 2026

Campari reported organic sales growth of 3.4% in Q3 2026 and 2.9% for the first nine months, its sixth consecutive quarter of growth, and reaffirmed full-year organic growth guidance of about 3% with EBIT margin guidance unchanged. Europe grew 3.8% and developing markets 9.3%, while North America grew 1% but the U.S. is expected to post a marginal full-year decline; APAC and global travel retail were down 0.4%. Campari collected a EUR 15 million tariff refund and cited about EUR 20 million of additional potential full-year tariff benefit pending finalization, while FX is expected to weigh on sales and EBIT. Shares were down 0.67% at $6.562; reported revenue and EPS were not provided, so no earnings surprise can be calculated.

Analysis

The key earnings-quality question is whether aperitif and tequila growth can offset weakness in the rest of the portfolio without diluting profit conversion. Management’s comments imply the new formats are not yet a margin windfall: co-manufacturing limits efficiency, and format-level gross margin is initially around group average. Distribution growth could therefore lift sales before it lifts EBIT or cash flow. A further risk is resource allocation: redirecting attention toward legacy brands may support recovery, but could dilute investment behind the higher-profit growth engines.

Near term, the U.S. category and comparison headwinds constrain upside despite strong sell-out in aperitifs and tequila. The tariff refund and currency effects complicate reading underlying margin progress; treat any benefit as non-recurring or externally driven until recurring conversion is demonstrated. Over 1–3 months, Q4 detail on U.S. brand trends, format cannibalization, and cash conversion matters more than the growth streak. Over 6–18 months, APAC’s reset and broader format rollout are potential growth levers, but execution and partner economics remain unproven.

The contrarian risk is that investors capitalize early-format velocity as durable, high-margin growth before scale economics are visible. Conversely, persistent weakness in legacy U.S. brands may be over-penalized if targeted retail execution improves. With no actual revenue or EPS figures supplied and valuation data absent, there is no clean event-driven trade or basis to claim a mispriced reaction.

Key Decisions for Investors

• No immediate directional position: do not interpret the reported operating trend as an earnings beat without actual revenue, EPS, and comparable consensus data.
• Watch for Q4 evidence that U.S. sell-out strength in aperitifs and tequila translates into reported sales, while tracking legacy-brand weakness and inventory alignment; deterioration in those measures would falsify the recovery case.
• Treat CPR as a conditional long, not a chase: reconsider after Q4 results or the March 2027 investor day if organic growth is supported by recurring EBIT and cash conversion, rather than tariff refunds or FX.
• Monitor format economics and execution: verify cannibalization, co-manufacturing costs, partner terms, and per-distribution velocity as launches scale; rising sales without margin or cash-flow improvement would weaken the structural thesis.